Ralf Brandt, who helped the metastatic cancer treatment company develop its drug PRP, returns to the board after resigning in 2018.
He spent seven years on the board before stepping down to oversee the merger of vivoPharm, an oncology discovery company he co-founded.
“We are pleased to welcome Dr. Brandt back to our scientific advisory board,” CEO James Nathanielsz said. “He played a pivotal role in advising the company, which enabled us to complete our preclinical development activities for the advancement of PRP to a first-in-human study in cancer patients. We look forward to his continued support and guidance, as we now focus our attention towards preparing for the planned clinical trial and progressing PRP through early stage clinical development.”
PRP is a treatment designed to target tumors in pancreatic, ovarian and colorectal cancers. Metastatic cancer, which Propanc focuses on, occurs when cancer cells spread to other areas of the body.
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel